Adjuvant trastuzumab induces ventricular remodeling despite aerobic exercise training

Clinical Cancer Research

Volumn 15, Issue 15, 2009, Pages 4963-4967

  Haykowsky, Mark J ^a   Mackey, John R ^b   Thompson, Richard B ^a   Jones, Lee W ^d   Paterson, D Ian ^c  

^a UNIVERSITY OF ALBERTA   (Canada)

^b CROSS CANCER INSTITUTE   (Canada)

^c UNIVERSITY OF ALBERTA HOSPITAL   (Canada)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; DOBUTAMINE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; TRASTUZUMAB;

ADULT; AEROBIC EXERCISE; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; DIASTOLIC BLOOD PRESSURE; EXERCISE TEST; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEART LEFT VENTRICLE VOLUME; HEART RATE; HUMAN; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; OXYGEN CONCENTRATION; PRIORITY JOURNAL; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; EXERCISE THERAPY; FEMALE; HUMANS; MIDDLE AGED; RECEPTOR, ERBB-2; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 68049139569     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-0628     Document Type: Article

References (27)

1. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707-712 (Pubitemid 19147683)
2. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Humanbreast cancer: correlation of relapse and survival with amplification of the HER-2/ neu oncogene. Science 1987;235:177-182
3. Smith I, Procter M, Gelber RD, et al. 2-year followup of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 2007;369:29-36. (Pubitemid 46039831)
4. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353:1673-1684 (Pubitemid 41464706)
5. Slamon D EW, Robert N, et al. Phase III trial comparing AC-T with AC-TH and with TCH in the adjuvant treatment of HER2 positive early breast cancer patients: second interim efficacy analysis. Presented at the San Antonio Breast Cancer Symposium; San Antonio, TX, December 14-17, 2006. 2006.
6. Suter TM, Procter M, van Veldhuisen DJ, et al. Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol 2007; 25:3859-3865 (Pubitemid 47477261)
7. Crone SA, Zhao YY, Fan L, et al. ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat Med 2002;8:459-465 (Pubitemid 34546747)
8. Ozcelik C, Erdmann B, Pilz B, et al. Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy. Proc Natl Acad Sci U S A 2002;99:8880-8885 (Pubitemid 34693652)
9. Vasan RS, Larson MG, Benjamin EJ, Evans JC, Levy D. Left ventricular dilatation and the risk of congestive heart failure in people without myocardial infarction. N Engl JMed 1997;336:1350-1355 (Pubitemid 27208618)
10. Cohn JN, Ferrari R, Sharpe N. Cardiac remodeling- concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling. J Am Coll Cardiol 2000;35:569-582
11. Haykowsky MJ, Liang Y, Pechter D, Jones LW, McAlister FA, Clark AM. A meta-analysis of the effect of exercise training on left ventricular remodeling in heart failure patients: the benefit depends on the type of training performed. J Am Coll Cardiol 2007;49:2329-2336 (Pubitemid 46891716)
12. Jones LW, Eves ND, Haykowsky M, Joy AA, Douglas PS. Cardiorespiratory exercise testing in clinical oncology research: systematic review and practice recommendations. Lancet Oncol 2008;9:757-765 (Pubitemid 352038314)
13. Tanaka H,MonahanKD,SealsDR.Age-predicted maximal heart rate revisited. J Am Coll Cardiol 2001;37:153-156
14. Fitzgerald MD, Tanaka H, Tran ZV, Seals DR. Age-related declines in maximal aerobic capacity in regularly exercising vs. sedentary women: a meta-analysis. J Appl Physiol 1997;83:160-165 (Pubitemid 27304745)
15. Katz J, Milliken MC, Stray-Gundersen J, et al. Estimation of human myocardial mass with MR imaging. Radiology 1988;169:495-498 (Pubitemid 18251115)
16. Segal R, Evans W, Johnson D, et al. Structured exercise improves physical functioning in women with stages I and II breast cancer: results of a randomized controlled trial. J Clin Oncol 2001;19: 657-665 (Pubitemid 32119079)
17. Courneya KS, Segal RJ, Mackey JR, et al. Effects of aerobic and resistance exercise in breast cancer patients receiving adjuvant chemotherapy: a multicenter randomized controlled trial. J Clin Oncol 2007;25:4396-4404
18. Wisloff U, Stoylen A, Loennechen JP, et al. Superior cardiovascular effect of aerobic interval training versus moderate continuous training in heart failure patients: a randomized study. Circulation 2007;115:3086-3094 (Pubitemid 46956498)
19. Spina RJ, Ogawa T, Coggan AR, Holloszy JO, Ehsani AA. Exercise training improves left ventricular contractile response to β-adrenergic agonist. J Appl Physiol 1992;72:307-311
20. McArthur HL, Chia S. Cardiotoxicity of trastuzumab in clinical practice.NEngl JMed2007;357:94-95
21. Chien KR. Herceptin and the heart-a molecular modifier of cardiac failure. N Engl J Med 2006; 354:789-790
22. Konstam MA, Rousseau MF, Kronenberg MW, et al. Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure. SOLVD Investigators. Circulation 1992;86:431-438
23. Wong M, Staszewsky L, Latini R, et al. Valsartan benefits left ventricular structure and function in heart failure: Val-HeFT echocardiographic study. J Am Coll Cardiol 2002;40:970-975 (Pubitemid 34994994)
24. Groenning BA, Nilsson JC, Sondergaard L, Fritz-Hansen T, Larsson HB, Hildebrandt PR. Antiremodeling effects on the left ventricle during β-blockade with metoprolol in the treatment of chronic heart failure. J Am Coll Cardiol 2000;36:2072-2080 (Pubitemid 32141511)
25. Tsutamoto T, Wada A, Maeda K, et al. Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure. J Am Coll Cardiol 2001;37:1228-1233 (Pubitemid 32295579)
26. Bellenger NG, Davies LC, Francis JM, Coats AJ, Pennell DJ. Reduction in sample size for studies of remodeling in heart failure by the use of cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2000;2:271-278
27. Bellenger NG, Burgess MI, Ray SG, et al. Comparison of left ventricular ejection fraction and volumes in heart failure by echocardiography, radionuclide ventriculography and cardiovascular magnetic resonance; are they interchangeable? Eur Heart J 2000;21:1387-1396